Co provides an update on the clinical development program for its oral thrombin receptor antagonist. Results from two randomized, double-blind, placebo-controlled Phase II studies in patients with ...
A single receptor in blood vessels can trigger either harmful inflammation or protective healing, but scientists have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results